By Jonathan Stempel NEW YORK (Reuters) -Bristol Myers Squibb won the dismissal of a proposed class action accusing it of ...

We recently published a list of the 10 High Growth Dividend Paying Stocks to Invest in. In this article, we are going to take ...

In a report released today, Terence Flynn from Morgan Stanley maintained a Sell rating on Bristol-Myers Squibb (BMY – Research Report), with a ...

High-yielding dividend stocks can be great investments to hold on to in your portfolio, but only if they're safe. Betting on ...

Bristol-Myers Squibb awarded its CEO nearly $19 million in compensation for 2024, following a challenging year for the ...

Bristol-Myers Squibb (NYSE:BMY – Get Free Report) was the target of a significant growth in short interest during the month ...

We recently published a list of 10 Firms End Friday Strong; 3 Reach All-Time Highs. In this article, we are going to take a ...

Investors seeking relief from stock market volatility should take a closer look at Bristol Myers Squibb (NYSE: BMY). At the ...

Today's Research Daily features new research reports on 16 major stocks, including Exxon Mobil Corporation (XOM), ...

Morgan Stanley lowered the firm’s price target on Bristol Myers (BMY) to $36 from $37 and keeps an Underweight rating on the shares. The firm ...

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology ...